Paper Details

  1. Home
  2. Paper Details

β3 adrenergic agonism: A novel pathway which improves right ventricular-pulmonary arterial hemodynamics in pulmonary arterial hypertension.

Author: CelermajerDavid S, CordinaRachael L, FigtreeGemma A, Karimi GalougahiKeyvan, KienzleVivian, LauEdmund, LiuChia-Chi, PatelSanjay, QuekLake-Ee, ZhangYunjia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pulmonary arterial hypertension (PAH) is characterized by reduced nitric oxide (NO) bioavailability due to endothelial nitric oxide synthase (eNOS) uncoupling. This study investigated the efficacy of β3 adrenergic receptor (β3 AR) agonism as a novel therapeutic approach for PAH. The β3 AR agonist CL316243 reduced right ventricular systolic pressure and reversed pulmonary vascular remodeling in experimental PAH models, similar to riociguat and sildenafil. CL316243 also improved right ventricular-pulmonary arterial coupling efficiency and reduced right ventricular stiffness, hypertrophy, and fibrosis. Notably, CL316243 significantly reduced eNOS glutathionylation, an oxidative modification that uncouples eNOS. These findings suggest that β3 AR agonists may be effective therapies for PAH.
Paper Details　
Original Abstract of the Article :
Efficacy of therapies that target the downstream nitric oxide (NO) pathway in pulmonary arterial hypertension (PAH) depends on the bioavailability of NO. Reduced NO level in PAH is secondary to "uncoupling" of endothelial nitric oxide synthase (eNOS). Stimulation of β3 adrenergic receptors (β3 ARs) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810839/

データ提供：米国国立医学図書館（NLM）

β3 Adrenergic Agonism: A New Oasis for Pulmonary Arterial Hypertension

This research delves into the promising world of β3 adrenergic agonists as a potential treatment for pulmonary arterial hypertension (PAH), a condition that can feel like navigating a desert with a heavy burden on your lungs. The study investigates the effects of stimulating β3 adrenergic receptors, aiming to find new pathways for relieving the pressure on the heart and lungs.

β3 Adrenergic Agonism: A New Oasis for Pulmonary Arterial Hypertension

The study found that β3 adrenergic agonism significantly improved right ventricular-pulmonary arterial hemodynamics in experimental models of PAH. This is like discovering a refreshing oasis in a desert of PAH, offering a new path to relief.

New Hope for Pulmonary Arterial Hypertension

This study provides hope for individuals with PAH, offering a potential new therapeutic avenue for managing this challenging condition. It’s like finding a new source of water in a parched desert, offering a ray of hope for those struggling with PAH.

Dr.Camel's Conclusion

This study suggests that β3 adrenergic agonists hold promise as a potential treatment for PAH. It’s like a camel caravan discovering a hidden oasis, offering a haven of relief and hope. Further research is needed to explore the clinical efficacy of β3 adrenergic agonists for PAH in humans.
Date :
  1. Date Completed 2023-01-05
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

36597221

DOI: Digital Object Identifier

PMC9810839

Related Literature

Article Analysis
・Effects of riociguat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.